New York, January 5, 2026, 10:58 (ET) — Regular session
- Eli Lilly shares fell about 3.4% as investors weighed fresh competition in oral weight-loss drugs.
- Rival Novo Nordisk began U.S. sales of a once-daily Wegovy pill with starter doses priced from $149 a month.
- Traders are looking ahead to Lilly’s next earnings update on Feb. 4.
Eli Lilly and Company shares fell about 3.4% on Monday, extending early losses after rival Novo Nordisk began selling a pill version of its Wegovy weight-loss drug in the United States. The stock was down at $1,043.14 after dipping nearly 4% earlier in the session.
The move puts the spotlight back on pricing power in obesity drugs, a market that has helped lift Lilly’s valuation and that investors treat as a multi-year growth engine. Novo said its once-daily Wegovy pill will start at $149 a month for self-paying patients, with higher doses priced at $299, as it pushes into a more consumer-driven channel for treatment.
That matters now because oral GLP-1 medicines — a class of drugs that mimic a gut hormone to curb appetite and lower blood sugar — are seen as a way to broaden access beyond weekly injections. Lower sticker prices for cash buyers can also reset expectations for how quickly insurers and employers will demand discounts across the category.
“Obesity has become a consumer-oriented disease,” Novo Nordisk CEO Mike Doustdar told TIME, as the company ramps production and distribution of the pill. TIME
The pressure showed up across health-care trading. The Health Care Select Sector SPDR ETF fell about 1.3% even as the S&P 500 tracker rose roughly 0.7%, while U.S.-listed Novo Nordisk shares gained about 2.9%.
For Lilly, the competitive focus is shifting to what it charges — and how quickly it can bring its own obesity pill to market. Novo’s launch follows a broader push toward cash-pay programs, including a planned direct-to-consumer TrumpRx site that Reuters reported is expected to launch this month, alongside steep list prices for injectable obesity drugs that run around $1,000 a month or more.
A key uncertainty is whether lower-priced pills expand the market or simply intensify a price fight that compresses margins. Investors will also watch for signs that demand shifts between pills and injections faster than manufacturers can manage supply, rebates and pharmacy coverage.
From a trading perspective, Lilly’s slide pulled the stock back toward the day’s lows, with investors watching whether it stabilizes around the $1,040 area after Monday’s dip. A break below that level would leave the psychologically important $1,000 mark as the next round-number area on some traders’ radar.
The next major checkpoint for Lilly is its fourth-quarter earnings call on February 4, when investors will look for commentary on obesity-drug demand, pricing strategy and any timeline updates for its pill program.
